This clinical trial is focused on studying treatments for children with certain types of blood cancers, specifically Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, which have either returned after treatment or have not responded to previous treatments. The study involves two medications: Venetoclax, also known by its code name ABT-199, and Ruxolitinib, which is sometimes referred to as INCB018424. These medications are being tested for their effectiveness in treating these cancers, particularly in cases where there are specific genetic changes in the IL-7R/JAK-STAT signaling pathway, which is a part of the body’s cell communication system that can affect cancer growth.
The purpose of the study is to evaluate the safety and effectiveness of these medications in children. Participants in the study will receive either Venetoclax or Ruxolitinib, or a combination of both, in the form of oral tablets or suspensions. The study will be conducted in two phases. The first phase will focus on determining the safest dose of the medications, while the second phase will assess how well the medications work in treating the cancers. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.
Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information on the potential benefits of Venetoclax and Ruxolitinib for children with these challenging types of blood cancers. The study is expected to continue until 2031, with recruitment starting in 2024.



Austria
Belgium
Denmark
Finland
France
Germany
Italy
Norway
Spain
Sweden
The Netherlands